

UNIVERSITY OF BIRMINGHAM

Research at Birmingham

Rejuvenation of the term Sarcopenia

Bulow, Jacob; Ulijaszek, Stanley J; Holm, Lars

DOI:

[10.1152/jappphysiol.00400.2018](https://doi.org/10.1152/jappphysiol.00400.2018)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Bulow, J, Ulijaszek, SJ & Holm, L 2018, 'Rejuvenation of the term Sarcopenia' *Journal of Applied Physiology*.
<https://doi.org/10.1152/jappphysiol.00400.2018>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Final version of record available at: <https://doi.org/10.1152/jappphysiol.00400.2018>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 **Title Page**

2

3 **Title**

4 Rejuvenation of the term Sarcopenia

5

6 **Running head**

7 Rejuvenation of the term Sarcopenia

8

9 **Authors**

10 Jacob Bülow MD¹, Stanley J. Ulijaszek PhD², Lars Holm PhD^{3,4}

11

12 **Author affiliations**

13 ¹Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital,
14 Copenhagen, Denmark

15 ²Institute of Social and Cultural Anthropology, University of Oxford, United Kingdom

16 ³Dept. of Biomedical Sciences, University of Copenhagen, Denmark

17 ⁴School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, United Kingdom

18

19 **Corresponding Author**

20 Jacob Bülow

21

22 Mailing address:

23 Institute of Sports Medicine Copenhagen M81,

24 Bispebjerg Hospital (Building 8, level 1),

25 Nielsine Nielsens Vej 11

26 2400 Copenhagen NV

27 Denmark

28

29 Tel: +45 38 63 53 98

30

31 e-mail: jacob.bulow@live.dk

32

33 **Sources of support**

34 Grant provided by P. Carl Petersen Fond, Stipend from RegionH.

35

36 **Word count**

37 1200 word excluding references.

38

39 **Conflict of interest declaration**

40 None of the authors declared any conflict of interest.

41

42

43

44

45

46 **Rejuvenation of the term Sarcopenia**

47 It is our viewpoint that the recent consensus definitions of Sarcopenia are dysfunctional for clinical and
48 experimental practice as well as in theory. In 1989 the term Sarcopenia was introduced to describe the
49 phenomenon of age related loss of lean body mass(10). Since 2010 six consensus definitions have been
50 presented, and in 2016 it was assigned its own ICD-10 code(1, 3, 5, 6, 8, 9, 11). A comparison of the
51 original definition with the new consensus definitions clarifies how the term Sarcopenia no longer describes
52 the phenomenon it originally addressed. Rather, the term is now caught in tautological association, which
53 causes confusion and hinders rather than helps understanding of this condition.

54 **The original definition**

55 In 1989, Rosenberg observed that the phenomenon of decreasing lean body mass with older age had not been
56 given the scientific attention it deserved, and drew attention to it, in suggesting a name combining the two
57 words *sarco* (meaning flesh) and *penia* (meaning loss), in accordance with the characteristic that it
58 described(10). The focus of this original definition was the loss of muscle mass as a discrete phenomenon,
59 with a leading interest in legitimizing clinical and scientific attention to it(10). This definition of Sarcopenia
60 was used descriptively with the purpose of defining and articulating the loss of skeletal muscle mass, as a
61 concrete object.

62 **The new consensus definitions**

63 Between 2011 and 2014, six consensus definitions of Sarcopenia were agreed (3, 5, 6, 8, 9, 11). These
64 shifted the focus from the original phenomenon of loss of skeletal muscle mass to that of physical function.
65 All of these definitions employ an algorithm with the same logic. Physical function capability is initially
66 assessed (gait speed or grip strength), and only if function is impaired below a cut-point, is muscle mass (as
67 the appendicular lean mass (ALM)) secondarily evaluated. Hence, low muscle mass is not a single stand-
68 alone determinant by which Sarcopenia is defined, and having only a low muscle mass is not an adequate
69 criterion by which to be defined as being Sarcopenic. Physical function is not synonymous with muscle
70 function although the concepts are sometimes used interchangeable in the six consensus articles. Physical

71 function is an interplay between multiple organ systems that can be estimated through tests like gait speed
72 whereas skeletal muscle, besides having the capability of contracting and allowing movement, has many
73 functions in metabolism and as an endocrine organ.
74 The consensus definitions were made by working groups, with representatives from different Societies
75 within the geriatric field, in Europe, the United States and Asia, two of them receiving partial funding from
76 the pharmaceutical industry. Discussion surrounding these definitions focusses most strongly on
77 determination of the exact cut-off values for both physical function tests and muscle mass measurements.
78 Surprisingly, the theoretical framework underpinning the definitions is not discussed thoroughly in any of the
79 articles and arguments for the inclusion of physical function is found in only three(5, 8, 11) of the six
80 papers. They share one main argument only, that the original definition is not clinically relevant.

81

82 **Questioning the reasoning for changing the definition**

83 The main argument for including physical function in the definition is at least two-fold. Firstly, if a well-
84 defined phenomenon is not clinically relevant, changing the definition does not make it become clinically
85 relevant. Instead, it changes the phenomenon under consideration. Secondly, every definition can become
86 clinically relevant by adding a criterion that is clinically relevant, as in this case with physical function. The
87 linking of loss of skeletal muscle mass to physical function reflects the logic behind the change of focus in
88 the research field of sarcopenia, which is notably absent from the consensus articles. During the 1990s there
89 was a research drive to develop operational criteria for cutoff values for categorizing adults as suffering from
90 Sarcopenia. The initial suggestion for an operational criterion and cutoff value was established by
91 Baumgartner in 1998, who legitimized the criterion by showing its association with a decrease in physical
92 function and mortality(2). This initiated the shift in focus from muscle mass to physical function. From
93 around 2000, the research focus shifted to considerations of how muscle strength and physical function such
94 as gait speed have stronger association than low muscle mass to a decrease in physical function and
95 mortality. Instead of concentrating on the loss of muscle mass, research interest centered on the robustness of
96 the phenomenon's association with decreased physical function and mortality, thereby making physical
97 function the primary object of interest.

98

99 From a clinical perspective it appears reasonable to focus on the phenomenon with the strongest association
100 to a negative health outcome. However, in this case the outcome and the phenomenon is almost, if not
101 exactly, identical, and the argument for the change of focus from muscle mass to physical function is a
102 tautology – arguing that there should be a change in focus from decreased muscle mass to decreased physical
103 function, since a decrease in physical function has a stronger association with a decrease in physical
104 function.

105

106 There are several consequences of the change in definition. According to the algorithms used in the
107 consensus definitions, skeletal muscle is only of value to the definitions if it is associated with bodily
108 movement. If gait speed is not reduced, presence of a low muscle mass is irrelevant according to the
109 consensus definitions. This is despite the fact that skeletal muscle is the largest metabolic organ of the body,
110 and is crucial in the endocrine regulation of metabolism as well as being the body's largest reservoir of
111 amino acids(7). Such functions are likely to be overlooked clinically when the primary inclusion criterion for
112 sarcopenia is physical function and not muscle mass. Likewise, physical function is at risk of being reduced
113 to the question of muscle mass when both are directly coupled in the definition(4). Further, it reduces the
114 relevance of the term in other clinical specialties such as nephrology and endocrinology, where muscle mass
115 per se could be of clinical importance for both categorizing patients as well as in selecting treatment. Beside
116 the reductionist understanding of the two different phenomena, the new definitions also lead to general
117 confusion of what is meant by the term Sarcopenia, since it no longer covers one but two phenomena.

118

119 **Conclusion**

120 Since the reasoning behind the change in definition of sarcopenia rests upon a tautological association, and
121 that the meaning of the term has become misleading as it no longer corresponds with the phenomenon that it
122 addresses, we suggest a return to the use of the original definition for future research. 'Sarcopenia' should
123 exclusively be used as a descriptive term addressing age-related loss of muscle mass. This would return
124 focus onto uncovering the causes and consequences of the phenomenon, and clinicians will hereby have an

125 unambiguous and useful term. Perhaps returning to the original definition could cause confusion in relation
126 to acceptance of age related loss of muscle mass as a clinical relevant phenomenon. However, the theoretical
127 foundations of the consensus definitions are tautological, and we anticipate that the consequences of these
128 definitions would continue to create confusion. There may be other and better definitions than the original
129 but since nobody will benefit from the current consensus definitions, breaking out of the tautology is
130 necessary to allow science and clinical practice to move on.

131

132 **References**

133

- 134 1. **Anker SD, Morley JE, von Haehling S.** Welcome to the ICD-10 code for sarcopenia. *J Cachexia*
135 *Sarcopenia Muscle* 7: 512–514, 2016.
- 136 2. **Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ,**
137 **Lindeman RD.** Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol* 147:
138 755–63, 1998.
- 139 3. **Chen L-K, Liu L-K, Woo J, Assantachai P, Auyeung T-W, Bahyah KS, Chou M-Y, Chen L-Y,**
140 **Hsu P-S, Krairit O, Lee JSW, Lee W-J, Lee Y, Liang C-K, Limpawattana P, Lin C-S, Peng L-**
141 **N, Satake S, Suzuki T, Won CW, Wu C-H, Wu S-N, Zhang T, Zeng P, Akishita M, Arai H.**
142 Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir*
143 *Assoc* 15: 95–101, 2014.
- 144 4. **Clark BC, Manini TM.** Sarcopenia \neq dynapenia. *J Gerontol A Biol Sci Med Sci* 63: 829–34, 2008.
- 145 5. **Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel**
146 **J-P, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M, European Working**
147 **Group on Sarcopenia in Older People.** Sarcopenia: European consensus on definition and
148 diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 39:
149 412–423, 2010.
- 150 6. **Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G,**
151 **Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De Meynard C, Donini L, Harris T,**
152 **Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami**
153 **E, Verlaan S, Zamboni M.** Sarcopenia: an undiagnosed condition in older adults. Current consensus
154 definition: prevalence, etiology, and consequences. International working group on sarcopenia. *J Am*
155 *Med Dir Assoc* 12: 249–56, 2011.
- 156 7. **Janssen I, Ross R.** Linking age-related changes in skeletal muscle mass and composition with
157 metabolism and disease. *J Nutr Health Aging* 9: 408–19.
- 158 8. **Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, Cederholm T, Coats**

- 159 **AJS, Cummings SR, Evans WJ, Fearon K, Ferrucci L, Fielding RA, Guralnik JM, Harris TB,**
160 **Inui A, Kalantar-Zadeh K, Kirwan B-A, Mantovani G, Muscaritoli M, Newman AB, Rossi-**
161 **Fanelli F, Rosano GMC, Roubenoff R, Schambelan M, Sokol GH, Storer TW, Vellas B, von**
162 **Haehling S, Yeh S-S, Anker SD, Society on Sarcopenia, Cachexia and Wasting Disorders**
163 **Trialist Workshop TS on, Workshop C and WDT.** Sarcopenia with limited mobility: an
164 international consensus. *J Am Med Dir Assoc* 12: 403–9, 2011.
- 165 9. **Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I,**
166 **Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM,**
167 **Schols A, Sieber CC.** Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document
168 elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and
169 “nutrition in geriatrics.” *Clin Nutr* 29: 154–9, 2010.
- 170 10. **Rosenberg IH.** Summary Comments. *Am J Clin Nutr* 50: 1231–1233, 1989.
- 171 11. **Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L,**
172 **Guralnik JM, Fragala MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam T-TL,**
173 **Vassileva MT.** The FNIH Sarcopenia Project: Rationale, Study Description, Conference
174 Recommendations, and Final Estimates. *Journals Gerontol Ser A Biol Sci Med Sci* 69: 547–558,
175 2014.
- 176